Dobutamine (Dobutrex®)

• Core dose: 2.5–20 mcg/kg/min IV infusion; start low and titrate to effect
• Onset/duration: Onset 1–2 min; peak effect ~10 min; half-life ~2–3 min; effects dissipate rapidly when stopped
• Key danger: Tachycardia, arrhythmias, hypotension (vasodilation at low doses), myocardial oxygen demand increase; may worsen ischemia
• Special: β1-selective inotrope; increases contractility and cardiac output with mild afterload reduction; preferred over dopamine for cardiogenic shock; requires central line for prolonged use

• Generic Name: Dobutamine hydrochloride
• Brand Names: Dobutrex® (legacy); premixed bags by Baxter/Hospira at 1–4 mg/mL

Inotrope; selective β1-adrenergic agonist (with β2 and α1 activity)

Mechanism of Action:

• Synthetic catecholamine racemate. The (+) enantiomer stimulates β1- and α1-receptors; the (–) enantiomer antagonizes α1
• Net effect at usual doses is increased myocardial contractility and stroke volume with mild vasodilation, raising cardiac output and reducing filling pressures
• At high doses, α1 effects may increase SVR

Pharmacokinetics:

• Onset: 1–2 min
• Peak: ~10 min
• Half-life: ~2–3 min
• Metabolism: Rapid hepatic/extrahepatic COMT (conjugation)
• Clearance: ~90 mL/kg/min
• Excretion: Urine as metabolites
• Vd: ~0.2 L/kg (ECF-confined)

• Acute decompensated heart failure or cardiogenic shock with low cardiac output and adequate MAP after fluids/vasopressor support
• Septic shock with persistent hypoperfusion or low ScvO₂ after fluids and adequate MAP (adjunct inotrope)
• Pharmacologic stress testing (dobutamine stress echocardiography)

• Acute decompensated heart failure with low cardiac output
• Cardiogenic shock
• Septic shock with persistent hypoperfusion (after adequate MAP achieved)
• Low cardiac output states requiring inotropic support

Available Forms:

• Premix bags: 100 mg/100 mL, 200 mg/100 mL, 400 mg/100 mL (in D5W)
• Vials: 12.5 mg/mL for dilution
• Typical concentration: 250 mg in 250 mL (1,000 mcg/mL); may concentrate up to 5,000 mcg/mL for fluid-restricted patients

Adult Dosing:

• Initial rate: 0.5–1 mcg/kg/min
• Common range: 2–20 mcg/kg/min
• Maximum: 40 mcg/kg/min
• Titrate to perfusion and adverse effects

Pediatrics/Neonates:

• Start: 0.5–1 mcg/kg/min
• Usual range: 2–20 mcg/kg/min
• Maximum: 40 mcg/kg/min
• Consider lower initial doses in premature neonates; titrate cautiously with continuous monitoring

Administration:

• Infuse via pump into a large peripheral vein or central line
• Use D5W or compatible solutions
• Avoid alkaline admixtures
• Continuous ECG and BP monitoring are required

Contraindications:

• Known hypersensitivity (including sulfites)
• Idiopathic hypertrophic subaortic stenosis (risk of dynamic LVOT obstruction)

Precautions:

• Use caution with atrial fibrillation (may accelerate ventricular response)
• Use caution with ischemic heart disease
• Use caution with severe hypotension without vasopressor support
• Correct hypovolemia and electrolytes before/while initiating therapy

Common:

• Tachyarrhythmias (PVCs, atrial fibrillation with rapid ventricular response)
• Palpitations
• Hypertension or hypotension
• Headache
• Nausea

Serious:

• Angina/myocardial ischemia
• Hypokalemia (especially with potassium-free solutions)
• Local phlebitis/extravasation reactions

• MAO inhibitors (e.g., phenelzine, tranylcypromine, linezolid): Hypertensive crisis/arrhythmias—avoid
• Tricyclic antidepressants: May potentiate or attenuate response—avoid or monitor closely
• Halogenated volatile anesthetics (isoflurane, sevoflurane): Sensitization to catecholamines—risk of ventricular arrhythmias
• Ergot derivatives/cabergoline: Additive vasospasm—avoid
• β-blockers: Antagonize inotropic response (may require higher doses); conversely, β-blockade may favor use of phosphodiesterase inhibitors
• Other sympathomimetics/β2-agonists: Additive tachycardia, hypertension, hypokalemia

Clinical Monitoring:

• Continuous ECG and noninvasive or invasive BP; consider arterial line in shock
• Perfusion endpoints: MAP ≥65 mmHg, improving mentation, warm extremities, urine output ≥0.5 mL/kg/h, lactate clearance, ScvO₂ ≥70% when used for persistent hypoperfusion
• Hemodynamics when available: CI, PCWP/CVP
• Signs of ischemia/arrhythmia

Laboratory Monitoring:

• Electrolytes (K⁺, Mg²⁺)
• Renal function

• 1. Medscape. (2024). Dobutamine (monograph). Retrieved November 11, 2025, from https://reference.medscape.com/drug/dobutamine-342434
• 2. Baxter Healthcare Corporation. (2023). Dobutamine Hydrochloride in 5% Dextrose Injection, USP [Prescribing information]. U.S. Food and Drug Administration.
• 3. Hospira, Inc. (2019). Dobutamine in 5% Dextrose Injection, USP [Prescribing information]. U.S. Food and Drug Administration.
• 4. Mathew, R., et al. (2021). Milrinone as compared with dobutamine in the treatment of cardiogenic shock. New England Journal of Medicine, 385(6), 516–525.
• 5. Evans, L., et al. (2021). Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. Intensive Care Medicine, 47, 1181–1247.
• 6. Papadopoulos, J. (2007). Pocket Guide to Critical Care Pharmacotherapy. Humana Press.